Evidence map›Paper›PMID 34934780›Full record

ArticleData in brief2021

Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data.

Danielle K Manning, Priyanka Shivdasani, Diane R Koeller, Alison Schwartz, Huma Q Rana, Judy E Garber, Neal I Lindeman, Arezou A Ghazani

Open access · goldAbstract read
In one paragraph

Article in Data in brief, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Development and evaluation of INTFrontiers in oncology · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Danielle K ManningDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Priyanka ShivdasaniDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Diane R KoellerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Alison SchwartzDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Huma Q RanaDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Judy E GarberDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Neal I LindemanDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Arezou A GhazaniDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) syndrome is a hereditary cancer genetic condition associated with inactivating pathogenic alterations in the

Indexed as

HemangioblastomaMatched tumor-germline dataNext generation sequencingRenal cell carcinomaVHL geneVon Hippel-Lindau

Identifiers

PMID34934780
PMCPMC8661471
OpenAlexW3214757783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.